Overview Phase I/IIa Study Evaluating Safety and Efficacy of an Intratympanic Dose of PIPE-505 in Subjects With Hearing Loss Status: Completed Trial end date: 2021-06-17 Target enrollment: Participant gender: Summary This is a randomized, double-blind study of PIPE-505, or placebo, in subjects with hearing loss associated with speech-in-noise impairment. Phase: Phase 1/Phase 2 Details Lead Sponsor: Pipeline Therapeutics, Inc.